Drug Profile


Alternative Names: CBD4124; CDB-4124; Proellex; Proellex®-V; Progenta; Telapristone acetate

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institute of Child Health and Human Development
  • Developer Northwestern University Feinberg School of Medicine; Repros Therapeutics
  • Class Antineoplastics; Antiprogestogens; Norpregnadienes; Small molecules
  • Mechanism of Action Selective progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Endometriosis; Uterine leiomyoma
  • Suspended Anaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Endometriosis in USA (Vaginal, Suppository)
  • 17 Jul 2017 Repros Therapeutics completes a phase II trial in Endometriosis in USA and Argentina (NCT01728454)
  • 01 May 2017 Repros Therapeutics terminates an extension phase II trial for Uterine leiomyoma in USA due to business decision (NCT02811159)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top